biostudies-literatureWu HQingfeng Scientific Research Fund of the China Crohn's & Colitis FoundationProject 1010 of Sixth Affiliated Hospital of Sun Yat-Sen UniversityProject 5010 of Sun Yat-Sen UniversityNational Natural Science Foundation of Chinathe program of Guangdong Provincial Clinical Research Center for Digestive DiseasesGuangzhou Science and Technology Fund190https://www.ebi.ac.uk/biostudies/studies/S-EPMC11761900biostudies-literatureUnknown13(1)<b>Background and Aims:</b> Inflammatory bowel disease (IBD) requires effective treatment options. Upadacitinib, a Janus kinase 1 (JAK1) inhibitor, has shown effectiveness in trials for Crohn's disease (CD) and ulcerative colitis (UC). This study evaluates its real-world effectiveness and safety. <b>Methods:</b> We conducted a multicenter retrospective cohort study in tertiary care centers, involving patients treated with upadacitinib from January 2023 to September 2024. The study included adult patients aged 18 years or older, diagnosed with UC or CD, who received at least 8 weeks of upadacitinib therapy. Treatment outcomes were evaluated using established clinical, endoscopic, imaging, histological, and laboratory parameters. <b>Results:</b> A total of 236 IBD patients received upadacitiBiomedicinesAn Analysis of the Effectiveness and Safety of Upadacitinib in the Treatment of Inflammatory Bowel Disease: A Multicenter Real-World Study.PMC117619001010PY(2020)-5581900490 81670477 and 822705442020B1111170004CCCF-QF-2022A53-2 and CCCF-QF-2022B43-1420140082024A03J0791Peng XXie TSu TYao JWu LYu QZhang MWang XZhi MWu HfalseAn Analysis of the Effectiveness and Safety of Upadacitinib in the Treatment of Inflammatory Bowel Disease: A Multicenter Real-World Study.<b>Background and Aims:</b> Inflammatory bowel disease (IBD) requires effective treatment options. Upadacitinib, a Janus kinase 1 (JAK1) inhibitor, has shown effectiveness in trials for Crohn's disease (CD) and ulcerative colitis (UC). This study evaluates its real-world effectiveness and safety. <b>Methods:</b> We conducted a multicenter retrospective cohort study in tertiary care centers, involving patients treated with upadacitinib from January 2023 to September 2024. The study included adult patients aged 18 years or older, diagnosed with UC or CD, who received at least 8 weeks of upadacitinib therapy. Treatment outcomes were evaluated using established clinical, endoscopic, imaging, histological, and laboratory parameters. <b>Results:</b> A total of 236 IBD patients received upadaciti2025-01-01T00:00:00Z2025 Jan2025-04-04T22:08:05.861Z2025-04-04T22:08:05.861ZS-EPMC117619003985777310.3390/biomedicines13010190